Background: Although diverticular disease is a common condition, its effective treatment is challenging in clinical practice. Objective: The objective of this article is to assess pharmacological management in different clinical settings of diverticular disease and factors associated with treatment using the Italian registry Registro Malattia Diverticolare (REMAD). Methods: At study enrolment, patients were categorised into subgroups: diverticulosis, symptomatic uncomplicated diverticular disease and previous diverticulitis. We registered demographic, clinical and lifestyle factors, quality of life and the use of treatments for diverticular disease in the last year. Logistic regression analysis assessed the association between clinical factors and treatment consumption. Results: A total of 500 of the 1206 individuals included had had at least one treatment for diverticular disease in the last year: 23.6% (166/702) of patients with diverticulosis, 55.9% (165/295) of patients with symptomatic diverticular disease, and 80.9% (169/209) of patients with previous diverticulitis (p<0.001). In multivariate analysis, the following factors were significantly associated with treatment use: female gender, family history of colonic diverticula, organic digestive comorbidity and impaired physical quality of life components. Conclusion: Individuals with diverticular disease take medications based on the different clinical settings of disease. We identified different features associated with treatment use in the distinct clinical entities of diverticular disease. ClinicalTrial.gov Identifier: NCT03325829.

Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry / Cremon, C; Carabotti, M; Cuomo, R; Pace, F; Andreozzi, P; Barbaro, Mr; Annibale, B; Barbara, G; on behalf of the REMAD, Group; Andrealli, A; Andriulli, A; Ardizzone, S; Astegiano, M; Bachetti, F; Bartolozzi, S; Bargiggia, S; Bassotti, G; Bianco, Ma; Binda, Ga; Biscaglia, G; Bosani, M; Bottiglieri, Me; Cargiolli, M; Ciacci, C; Colecchia, A; Dell’Era, A; De Matthaeis, M; Dinelli, M; Festa, V; Festi, D; Galliani, E; Garribba, A; Germana’, B; Grassini, M; Guido, E; Iafrate, F; Iovino, P; Iuliano, D; Laghi, A; Latella, G; Lorusso, M; Manes, G; Marchi, S; Mauro, B; Maurano, A; Nascimbeni, R; Neri, M; Occhipinti, P; Parravicini, M; Pennazio, M; Peralta, S; Portincasa, P; Radaelli, F; Rossi, M; Salerno, R; Savarino, V; Segato, S; Severi, C; Scaccianoce, G; Usai, P; Valle, V; Virgilio, C; Viscido, A. - In: UNITED EUROPEAN GASTROENTEROLOGY JOURNAL. - ISSN 2050-6406. - 7:6(2019), pp. 815-824. [10.1177/2050640619845990]

Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry

Carabotti M;Annibale B;Iafrate F;Laghi A;Severi C;
2019

Abstract

Background: Although diverticular disease is a common condition, its effective treatment is challenging in clinical practice. Objective: The objective of this article is to assess pharmacological management in different clinical settings of diverticular disease and factors associated with treatment using the Italian registry Registro Malattia Diverticolare (REMAD). Methods: At study enrolment, patients were categorised into subgroups: diverticulosis, symptomatic uncomplicated diverticular disease and previous diverticulitis. We registered demographic, clinical and lifestyle factors, quality of life and the use of treatments for diverticular disease in the last year. Logistic regression analysis assessed the association between clinical factors and treatment consumption. Results: A total of 500 of the 1206 individuals included had had at least one treatment for diverticular disease in the last year: 23.6% (166/702) of patients with diverticulosis, 55.9% (165/295) of patients with symptomatic diverticular disease, and 80.9% (169/209) of patients with previous diverticulitis (p<0.001). In multivariate analysis, the following factors were significantly associated with treatment use: female gender, family history of colonic diverticula, organic digestive comorbidity and impaired physical quality of life components. Conclusion: Individuals with diverticular disease take medications based on the different clinical settings of disease. We identified different features associated with treatment use in the distinct clinical entities of diverticular disease. ClinicalTrial.gov Identifier: NCT03325829.
File allegati a questo prodotto
File Dimensione Formato  
Cremon_Italian nationwide survey_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 264.23 kB
Formato Adobe PDF
264.23 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1303028
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact